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1) Division of Infectious Diseases and Hospital Epidemiology and 2) Division of Clinical Microbiology, University Hospital Basel, Basel, SwitzerlandAbstractThe optimal approach in laboratory diagnosis of Clostridium difﬁcile infection (CDI) is still not well deﬁned. Toxigenic culture (TC) or
alternatively fecal toxin assay by cell cytotoxicity neutralization assay are considered to be the reference standard, but these methods are
time-consuming and labor intensive. In many medical centers, diagnosis of CDI is therefore still based on fecal toxin A/B enzyme
immunoassay (EIA) directly from stool alone, balancing cost and speed against limited diagnostic sensitivity. The aim of the study was to
assess in which patient population the additional workload of TC is justiﬁed. All consecutive stool specimens submitted for diagnosis of
suspected CDI between 2004 and 2011 at a tertiary-care center were examined by toxin EIA and TC. Clinical data of patients with
established diagnosis of CDI were collected in a standardized case-report form. From 12 481 stool specimens submitted to the
microbiologic laboratory, 480 (3.8%) fulﬁlled CDI criteria; 274 (57.1%) were diagnosed by toxin EIA; and an additional 206 (42.9%) were
diagnosed by TC when toxin EIA was negative. Independent predictors for negative toxin EIA but positive TC were high-dose
corticosteroids (odds ratio (OR) 2.97, 95% conﬁdence interval (CI) 1.50–5.90, p 0.002), leukocytopenia <1000/μL (OR 2.52, 95% CI
1.22–5.23, p 0.013) and nonsevere CDI (OR 2.21, 95% CI 1.39–3.50, p 0.001). There was no difference in outcomes such as in-hospital
mortality and recurrence between both groups. In conclusion, negative toxin EIA does not rule out CDI in immunocompromised
patients in the setting of relevant clinical symptoms. Methods with improved sensitivity such as TC or PCR should be used, particularly in
this patient population.
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E-mail: Andreas.Widmer@usb.chIntroductionPrevalence of Clostridium difﬁcile, the most frequent cause of
nosocomial diarrhoea, is rapidly increasing [1–4]. Despite this,
the optimal approach in laboratory diagnosis of Clostridium
difﬁcile infection (CDI) is still not well deﬁned [1,5–7]. Toxi-Microbiol Infect 2015; 21: 998.e9–998.e15
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.07.016genic culture (TC) or fecal toxin assay by cell cytotoxicity
neutralization assay are regarded the reference standard for
diagnosis of CDI [1,8]. These methods are time-consuming and
labor intensive. In many medical centers, diagnosis of CDI is
therefore still based on fecal toxin A/B enzyme immunoassay
(EIA) directly from stool (toxin EIA) alone, balancing cost and
speed against limited diagnostic sensitivity [6,9–13].
A two-step diagnostic algorithm was published and validated
using EIA detection of GDH as initial screening, followed by
fecal toxin A/B-EIA of GDH-positive samples. Toxin-negative
specimens were further examined with TC. With this
approach, >90% of CDI could be diagnosed with reduced
turnaround time [14].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Erb et al. Fecal toxin A/B enzyme immunoassay 998.e10In the last few years, PCR methods for detection of genes
encoding C. difﬁcile toxin B have become more widely available
and used in the diagnosis of CDI, but its high cost is a major
drawback [12,15,16]. Despite this diagnostic progress, the
clinical signiﬁcance of a positive PCR or TC in patients with a
negative toxin EIA remains controversial. The higher sensitivity
of these tests may also identify colonization of toxigenic
C. difﬁcile in asymptomatic patients or patients with diarrhoea
for other reasons, raising the question if treatment for all cases
is justiﬁable [11,17–21].
We therefore aimed to determine the clinical characteris-
tics and outcome of CDI diagnosed by positive TC in the
setting of a negative toxin EIA in order to identify patients
mostly beneﬁting from additional conﬁrmatory laboratory
testing and patients in whom TC might be omitted to save time
and money.MethodsThe microbiology laboratory at the University Hospital Basel,
Switzerland, a tertiary-care center, processes approximately
80 000 samples per year from an average of 34 000 patients. All
consecutive stool specimens submitted for C. difﬁcile between
2004 and 2008 were analysed by C. difﬁcile culture and detec-
tion of fecal toxin A/B by EIA (CDIFF TOX A/B II; TechLab/
Wampole, Blacksburg, VA, USA) directly from stool (toxin EIA)
according to the manufacturer’s instructions.
Stool cultures were plated on selective cycloserine–
cefoxitin–blood agar plates (CLO agar; bioMérieux, Marcy
l’Etoile, France) and incubated in an anaerobic chamber for 48
hours. C. difﬁcile colonies were identiﬁed on the basis of their
typical morphology on agar plates and by Gram stain, charac-
teristic odor and unique pattern of fatty acid metabolic prod-
ucts by gas– liquid chromatography [14].
Toxin detection from positive culture (i.e. TC) was per-
formed when direct fecal toxin was negative [14].
In 2008, a two-step approach with screening for C. difﬁcile
glutamate dehydrogenase antigen (GDH) (Wampole C.DIFF
CHEK-60) was introduced for all stool samples, and only pos-
itive stools were further evaluated for C. difﬁcile toxin by EIA or
TC. Processing of the stool samples was done as described
elsewhere [14]. PCR ribotyping to detect hypervirulent PCR
ribotype 027 was done in all C. difﬁcile strains resistant to
moxiﬂoxacin [22,23].
In addition, stool cultures for Salmonella, Campylobacter and
Shigella spp. were done for all patients.
Clinical data of all patients >18 years with CDI were
collected by a standardized case report form from patient full-
chart review.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfThe study was approved by the local ethics committee as
part of the quality assurance program.
Deﬁnitions
CDI was deﬁned according to the European Society of Clinical
Microbiology and Infectious Diseases (ESCMID) guidelines
[5,24] by clinical symptoms compatible with CDI including
diarrhoea, pseudomembranous colitis, ileus or toxic mega-
colon, and microbiologic evidence of free toxin and the pres-
ence of C. difﬁcile in stool.
CDI was classiﬁed as severe according to the deﬁnition
proposed by the ESCMID [5,24]. All other cases not the ful-
ﬁlling criteria of severe CDI were classiﬁed as nonsevere.
Clinically and microbiologically conﬁrmed CDI occurring
within 8 weeks after previous resolution of diarrhoea was
considered as recurrence, and beyond 8 weeks was considered
a new episode [25].
Chemotherapy included all substances directed against can-
cer such as alkylating agents or antimetabolites used in the last 3
months before diagnosis of CDI. Immunosuppressive drugs
included all types of agents to prevent graft rejection in solid
organ or human stem cell/bone marrow transplantation
(HSCT) such as calcineurin inhibitors or mycophenolate, and to
treat autoimmune diseases with monoclonal antibodies such as
tumor necrosis factor α inhibitors used in the last 3 months.
High-dose corticosteroids were separately reported if patients
received prednisone equivalent of 1 mg/kg body weight in the
last 7 days before CDI diagnosis. Gastrointestinal manipulation
included insertion of nasogastric tube or endoscopy in the last 7
days.
Data of previous use of antibiotics were collected up to 30
days before diagnosis of CDI.
Statistical analysis
Univariable analysis was performed by the chi-square test or
Fisher’s exact test, where appropriate, for categorical variables
and two-tailed Student’s t test for continuous variables if data
were normally distributed. Subgroup analysis was done for
immunocompromised patients, deﬁned as having low white
blood cell count (WBC) <1000/μL, HSCT, immunosuppressive
drug therapy, chemotherapy and/or high-dose corticosteroids.
In order to identify possible confounding factors, all variables
found to be signiﬁcant in univariable analyses were included in
the multivariable regression models after calculating odds ratios
by logistic regression. Stepwise logistic regression using step-
wise forward and backward selection was applied to identify
variables independently associated with negative toxin EIA but
positive TC. Two-sided p values of <0.05 were considered
signiﬁcant. Analyses were performed by Stata 12.0 (StataCorp,
College Station, TX, USA).ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 998.e9–998.e15
998.e11 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIResultsA total of 12 481 consecutive stool specimens were submitted
to the microbiologic laboratory for C. difﬁcile diagnostics during
the study period from 2004 until 2011 (Fig. 1). Four hundred
eighty patients (3.8%) fulﬁlled the criteria for CDI, of whom 274
(57.1%) were diagnosed by positive toxin EIA and additional
206 (42.9%) by positive TC, toxin EIA being negative. Seven
patients (1.5%) had hypervirulent C. difﬁcile PCR ribotype 027.
Additional enteropathogenic bacteria such as Salmonella enterica
serotype Enteritidis and Campylobacter spp. were detected in 10
patients (2.3%) by conventional stool culture.
Clinical and outcome parameters were compared between
CDI patients with positive toxin EIA and those with negative
toxin EIA but positive TC (Table 1). Age, sex, underlying dis-
ease (Charlson comorbidity index and McCabe score) and fever
at onset were equally distributed between the two groups.
In univariable analysis,CDI patientswith leukocytopenia<1000/
μL signiﬁcantly more often had a negative toxin EIA but a positive
TC. In contrast, patients with higher levels of WBC were more
likely to be diagnosed by a positive toxin EIA, suggesting better
sensitivity of the toxin EIA in patients with leukocytosis.
Furthermore, patients with positive TC only more
commonly received high-dose corticosteroids (prednisoneClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectequivalent 1 mg/kg body weight), immunosuppressive treat-
ment or chemotherapy. They more often had HSCT, were
hospitalized more frequently in the hematology unit, more
often had a nonsevere clinical course of the CDI and were less
likely to receive appropriate antibiotic treatment for CDI with
metronidazole or vancomycin compared to the CDI patients
with positive toxin EIA.
In contrast, C-reactive protein >40 mg/L, previous antibiotic
exposure, surgery, gastrointestinal manipulations and intuba-
tion, and severe CDI were found more frequently in patients
with positive toxin EIA.
Outcome was similar in both groups: surgical intervention
was needed in 3 (1.1%) and 3 (1.5%), transfer to an intensive
care unit because of CDI in 47 (17.2%) and 30 (14.6%),
recurrent CDI detected in 31 (11.3%) and 17 (8.3%), crude in-
hospital mortality 7.7% and 7.8% and in-hospital mortality
attributed to CDI 3.3% and 1.5% in patients with positive toxin
EIA and patients with positive TC only, respectively (Table 1).
CDI patients who were diagnosed by TC started treatment
with a mean delay of 2.3 days (standard deviation (SD) 2.29)
compared to 0.9 days (SD 1.49) in patients diagnosed by toxin
EIA (p <0.001); however, there was no detectable difference in
outcome.
One hundred twenty-two of the 480 patients with CDI were
immunocompromised, as deﬁned in Methods. Among them, 57FIG. 1. Enrollment and results of CDI
patients with toxin EIA and TC. CDI,
Clostridium difﬁcile infection; EIA, enzyme
immunoassay; ESCMID, European Soci-
ety of Clinical Microbiology and Infec-
tious Diseases; GDH, C. difﬁcile glutamate
dehydrogenase antigen (from 2008 on-
wards); nontoxigenic C. difﬁcile: culture
positive for C. difﬁcile, but toxin EIA
directly from stool and TC negative; TC,
toxigenic culture.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 998.e9–998.e15
TABLE 1. Clinical features, risk factors, therapy and outcome of patients with Clostridium difﬁcile infectiona
Characteristic
Toxin-EIA positive
(n [ 274)
TC positive, toxin EIA
negative (n [ 206) OR 95% CI p
Male sex, n (%) 126 (46.0) 110 (53.4) 1.35 0.94–1.93 0.108
Age (years), mean (SD) 66.7 (15.3) 64.6 (17.4) 0.99 0.98–1.00 0.164
McCabe score, n (%)
Nonfatal + fatal <5 years 246 (89.8) 183 (88.8) 1.10 0.62–2.00 0.739
Fatal <6 months 28 (10.2) 23 (11.2)
Charlson index, mean (SD) 2.71 (2.41) 2.71 (2.2) 1.00 0.92–1.08 0.990
PCR ribotype 027, n (%) 5 (1.8) 2 (1.0) 1.90 0.36–9.87 0.482
Previous use of antibiotics, n (%)b
Any antibiotics 239 (87.2) 163 (79.1) 0.56 0.34–0.91 0.018
Penicillin 14 (5.1) 6 (2.9)
Penicillin and β-lactamase inhibitor 144 (52.6) 94 (45.6)
Cephalosporins 124 (45.3) 82 (39.8)
Carbapenems 34 (12.4) 30 (14.6)
Quinolones 42 (15.3) 23 (11.2)
Aminoglycosides 24 (8.8) 24 (11.7)
Glycopeptides 4 (1.5) 11 (5.3)
Other antibiotics 96 (35.0) 63 (30.6)
Clinical and laboratory parameters
Temperature 38°C, n (%) 170 (62.0) 116 (56.3) 0.79 0.55–1.14 0.206
WBC <1000/μL, n (%) 13 (4.8) 25 (12.1) 2.77 1.38–5.57 0.004
WBC (/μL), median (IQR) 11 070 (7310–16 290) 7890 (4600–12 2800) 0.94c 0.91–0.96 <0.001
C-reactive protein >40 mg/L, n (%) 187 (68.2) 121 (58.7) 0.66 0.45–0.96 0.032
Creatinine (μmol/L), mean (SD) 128.5 (145.36) 126.0 (134.21) 1.00 1.00–1.00 0.850
Classiﬁcation CDAD, n (%)
Not severe 187 (68.2) 167 (81.1) 2.08 1.33–3.22 0.001
Severe 86 (31.5) 37 (18.1)
Predisposing factors, n (%)d
High-dose corticosteroids 16 (5.8) 29 (14.1) 2.64 1.39–5.01 0.003
Cancer/chemotherapy 41 (15) 54 (26.2) 2.02 1.28–3.18 0.002
Immunosuppressive drug therapy 31 (11.3) 39 (18.9) 1.83 1.10–3.07 0.020
Proton pump inhibitor 179 (65.3) 144 (69.9) 0.81 0.55–1.20 0.291
Previous surgery 116 (42.8) 63 (30.9) 0.60 0.41–0.87 0.008
HSCT 14 (5.3) 31 (15.7) 3.29 1.70–6.36 <0.001
Gastrointestinal manipulation 75 (27.4) 36 (17.5) 0.56 0.35–0.88 0.011
Intubation 47 (17.2) 21 (10.2) 0.55 0.32–0.96 0.034
Hospitalization, n (%)
Hematology unit 12 (4.4) 29 (14.1) 3.58 1.78–7.20 <0.001
ICU 26 (9.4) 11 (5.3) 0.54 0.26–1.12 0.096
Medicine ward 133 (48.5) 109 (52.9) 1.19 0.83–1.71 0.340
Surgical ward 86 (31.4) 52 (25.2) 0.74 0.49–1.11 0.142
Geriatric ward 17 (6.2) 5 (2.4) 0.38 0.14–1.04 0.059
Therapy of CDAD, n (%)
Metronidazole 251 (91.6) 158 (76.7) 0.30 0.18–0.51 <0.001
Vancomycin 28 (10.2) 7 (3.4) 0.31 0.13–0.72 0.007
Saccharomyces boulardii 60 (21.9) 30 (14.6) 0.61 0.78–0.98 0.043
No therapy 10 (3.6) 42 (20.4) 6.76 3.30–13.84 <0.001
Outcome follow-up, n (%)
Need for surgery 3 (1.1) 3 (1.5) 1.12 0.52–2.61 0.727
Transfer to ICU 47 (17.2) 30 (14.6) 0.92 0.76–1.13 0.454
Recurrence 31 (11.3) 17 (8.3) 0.71 0.38–1.31 0.270
Crude mortality <30 days 7 (2.6) 7 (3.4) 1.34 0.46–3.89 0.588
Crude in-hospital mortality 21 (7.7) 16 (7.8) 1.01 0.52–2.00 0.967
CDI-attributable in-hospital mortality 9 (3.3) 3 (1.5) 0.64 0.38–1.08 0.121
CDAD, Clostridium difﬁcile–associated diarrhoea; CDI, C. difﬁcile infection; CI, conﬁdence interval; EIA, enzyme immunoassay; HSCT, human stem cell/bone marrow transplantation;
ICU, intensive care unit; IQR, interquartile range; OR, odds ratio; SD, standard deviation; WBC, white blood cell count.
aPatients with positive direct toxin A/B from stool (toxin EIA positive) and patients with positive toxigenic culture when toxin EIA was negative (TC positive, toxin EIA negative).
bIn the last 30 days before diagnosis of CDI.
cOR refers to every 1000/μL increase of WBC.
dFor predisposing factors, high-dose corticosteroids refers to prednisone-equivalent  1 mg/kg body weight per day in last 7 days; chemotherapy included all substances directed
against cancer such as alkylating agents or antimetabolites used in the last 3 months before diagnosis of CDI; immunosuppressive drugs included all types of agents to prevent graft
rejection in solid organ or human stem cell/bone marrow transplantation such as calcineurin inhibitors or mycophenolate, and biologicals such as tumor necrosis factor α inhibitors
used in the last 3 months (excluding corticosteroids); proton pump inhibitor administered and intubation provided in last 7 days before diagnosis of CDI; previous surgery in the last
3 months before diagnosis of CDI; and gastrointestinal manipulation included insertion of nasogastric tube or endoscopy in the last 7 days.
CMI Erb et al. Fecal toxin A/B enzyme immunoassay 998.e12patients had a positive toxin EIA and 65 patients a positive TC
only. In this subgroup, patients with positive TC in case of
negative toxin EIA and patients with positive toxin EIA directly
from stool had similar comorbidities (McCabe score fatal <6
months 24.6% and 33.3% (conﬁdence interval (CI) 95%
0.65–3.64, p 0.39), Charlson index 3.0 (SD 1.8) and 3.8 (SD
2.6) (CI 95% 0.01–1.63, p 0.077), respectively). There was no
difference in severity of CDI (nonsevere CDI 83.1% and 73.7%,
CI 95% 0.23–1.38, p 0.22) and outcome (recurrence of 13.8%
and 10.5%, CI 95% 0.56–1.37, p 0.58) and crude in-hospitalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infmortality of 13.8% and 7% (CI 95% 0.27–1.46, p 0.25). Pa-
tients were treated as often for CDI (95.1% and 98.2%, CI 95%
0.65–48.8, p 0.16) in both groups.
A multivariable logistic regression model using stepwise
forward and backward selection was applied to identify vari-
ables independently associated with negative toxin EIA but
positive TC. All variables found to be signiﬁcant in univariable
analyses were included in the multivariable regression models:
immunosuppressive drug therapy, high-dose corticosteroids,
chemotherapy, HSCT, previous antibiotic treatment, WBCectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 998.e9–998.e15
998.e13 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMI<1000/μL, C-reactive protein >40 mg/L, CDI severity, previous
surgical intervention, gastrointestinal manipulations, intubation
and hospitalization in the hematology unit. In the ﬁnal model,
the following predictors were independently associated with
negative toxin EIA and positive TC (Table 2): high-dose corti-
costeroids, low WBC <1000/μL and nonsevere CDI. Previous
antibiotic use and gastrointestinal manipulation were predictors
for positive toxin EIA.DiscussionIn our study, we compared the clinical characteristics and
outcome of 480 CDI patients diagnosed by positive toxin EIA
with those detected by TC in the setting of a negative toxin EIA.
We found that CDIs were diagnosed only in 57% by toxin EIA
and that especially in immunocompromised patients, a negative
toxin EIA did not rule out CDI in the setting of relevant clinical
symptoms.
Interestingly, the toxin EIA performed poorly particularly in
patients with leukocytopenia <1000/μL, requiring TC for
diagnosis of CDI, whereas patients with higher WBC were
more likely to have a positive fecal toxin EIA (p <0.001).
In the multivariable analysis, the strongest predictors for
negative toxin EIA and positivity of TC only were severe leu-
kocytopenia with WBC <1000/μL and intake of high-dose
corticosteroids. Hematologic patients including patients after
HSCT, patients with chemotherapy or immunosuppressive
therapy and patients with corticosteroids were mainly affected.
Any explanation of this observation remains hypothetical so far.
Treatment of their underlying disease frequently results in se-
vere damage and disruption of the intestinal mucosa and normal
ﬂora and facilitates colonization of C. difﬁcile. Under these cir-
cumstances, a low burden of toxin A/B can already cause CDI-
like symptoms and can provoke rapid diagnostic steps in these
vulnerable patients. Many of these patients usually receiveTABLE 2. Multivariable analysis of predictors for negative
toxin EIA and positivity of toxigenic culturea
Risk factor OR (95% CI) p
High-dose corticosteroids 2.97 (1.50–5.90) 0.002
Low WBC <1000/μL 2.52 (1.22–5.23) 0.013
Nonsevere CDI 2.21 (1.39–3.50) 0.001
Antibiotic use before CDI 0.50 (0.30–0.83) 0.007
Gastrointestinal manipulation 0.58 (0.36–0.94) 0.026
CDI, Clostridium difﬁcile infection; CI, conﬁdence interval; EIA, enzyme
immunoassay; OR, odds ratio; WBC, white blood cell count.
aAll variables found to be signiﬁcant in univariable analyses were included in
multivariable regression models: immunosuppressive drug therapy, high-dose
corticosteroids, chemotherapy, hematopoietic stem cell transplantation, previous
antibiotic treatment, WBC <1000/μL, C-reactive protein >40 mg/L, CDI severity,
previous surgical intervention, gastrointestinal manipulations, intubation, and
hospitalization in hematology unit.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectintravenous immunoglobulin therapy for their underlying dis-
ease, which may possibly bind C. difﬁcile toxin A/B. Immuno-
globulins are provided also as therapeutic adjunct particular in
severe CDI, although their beneﬁt is controversial [26].
Most published data suggest that CDI is more common in
immunocompromised patients like HSCT recipients than in
nonimmunocompromised patients [27–29]. The diagnosis of
CDI in immunocompromised patients remains problematic.
The increasing use of more sensitive tests like PCR or TC may
result in increased detection of toxin-producing C. difﬁcile cases,
but also to some degree in misclassiﬁcation of colonized-only
patients without CDI [27]. To our knowledge, this is the ﬁrst
study showing that immunocompromised patients in particular
are prone to have negative direct toxin EIA results, suggesting
that these patients may beneﬁt from additional conﬁrmatory
laboratory testing by PCR or TC in the presence of relevant
clinical symptoms.
The literature also remains controversial concerning disease
severity and outcome in CDI patients detected by direct fecal
toxin assay compared to more sensitive methods like TC or
PCR [11,15,17–20,30,31]. Because only patients fulﬁlling the
ESCMID deﬁnition of CDI were included in our study, we do
not believe that in patients with negative toxin EIA positivity of
TC represents only asymptomatic C. difﬁcile colonization.
However, particularly in patients with mild CDI, causes of
diarrhoea other than C. difﬁcile cannot be excluded completely.
It is noteworthy that patients with CDI detected by positive
TC (in case of negative toxin EIA) less frequently received
treatment with metronidazole or vancomycin compared to
those with positive toxin EIA, most likely because of the higher
rate of mild CDI in patients with TC only. However, both
groups had similar outcomes concerning need for surgery,
transfer to intensive care unit, recurrence, crude mortality and
CDI-attributable mortality. This approach correlates with the
ESCMID guidelines regarding treatment of mild CDI [5,24]
because spontaneous recovery without antibiotic therapy
probably occurs in approximately one-third of these patients
[32]. Immunocompromised patients, in contrast, almost always
received CDI treatment, either in those with positive toxin EIA
or in those with positive TC only (95.1% and 98.2%, respec-
tively, CI 95% 0.65–48.8, p 0.16). The severity of the disease
and the outcome were also the same in both groups, again
suggesting true CDI rather than asymptomatic colonization in
immunocompromised patients with positive TC only.
Similar results have been reported by Kaltsas et al. [18] in a
mainly immunocompromised patient collective with malig-
nancies. No signiﬁcant differences were observed in symptoms
or in the severity of CDI cases, or in outcome between patients
who were tested positive by cell cytotoxicity neutralization
assay compared to those who were tested positive by PCR only.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 998.e9–998.e15
CMI Erb et al. Fecal toxin A/B enzyme immunoassay 998.e14These and our results are in contrast to the ﬁndings of a
recent study by Planche et al. [17], in which patients with a
positive direct fecal toxin assay had a higher mortality than
patients with positive TC but negative toxin assay. The authors
concluded that CDI should be conﬁrmed by a fecal toxin test
rather than by TC. However, our study provides detailed
clinical data of the patient population, including immunocom-
promised patients, who are not described by Planche et al.
Finally, in multivariable analysis, previous exposure to antibi-
otics and gastrointestinal manipulations like nasogastric tube or
endoscopy were predictive for having positive toxin EIA test
directly from stool. It is well known that previous antibiotic use is
a strong risk factor for CDI, as it promotes overgrowth of toxin-
producing C. difﬁcile [3,33]. In patients unexposed to antibiotics,
normal gut ﬂora is more preserved andmight inhibit high C. difﬁcile
toxin production, thus explaining the higher detection rate with
TC in these patients. The role of gastrointestinal manipulation in
the pathogenesis of CDI remains controversial [34].
Our study has several limitations that may possibly limit its
generalizability to other settings. These include its single-centre
design and its reliance on retrospective medical chart review
for classiﬁcation of disease severity and prior antimicrobial
exposure. The low recurrence rate—only 10%—could be
explained by the lack of postdischarge data but also by the low
incidence of hypervirulent C. difﬁcile PCR ribotype strain 027 in
our study population [35–37]. Our diagnostic study protocol
was slightly changed during the study period by introducing a
two-step algorithm with GDH screening of stool in 2008.
Finally, not all patients received a full comprehensive stool
workup for causes other than C. difﬁcile.
In conclusion, the toxin EIA has a low sensitivity of only 57%,
as shown in our study, indicating that almost half of all CDIs will
be missed if relying only on toxin EIA. TC—and more recently
also PCR—methods have increased the sensitivity in the diag-
nosis of CDI compared to the widely used toxin EIA, but they
have drawbacks, including long turnaround time and high cost,
respectively. Not all, but a substantial percentage of, CDI pa-
tients with negative toxin EIA and positive TC require treat-
ment. With the increasing incidence of CDI and ﬁnancial
pressure on many healthcare systems with respect to resource
utilization, focus has turned to improving and optimizing diag-
nostic modalities for early and accurate detection of CDI. In
nonimmunocompromised patients with a mild clinical course of
CDI and negative toxin EIA, it is probably justiﬁable to omit TC
or PCR while closely monitoring the patient because CDI
diagnosis may be missed and spontaneous recovery without
antibiotic may occur [32]. In contrast, in immunocompromised
patients with clinical signs of CDI, it is essential to perform
conﬁrmatory laboratory testing with PCR or TC in the pres-
ence of negative toxin EIA.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfTransparency DeclarationThis study was supported by an unrestricted educational grant
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